Resistance to Targeted Therapy in Chronic Myelogenous Leukemia
Author:
Publisher
Elsevier BV
Subject
Hematology
Reference70 articles.
1. Imatinib as a paradigm of targeted therapies;Druker;Adv Cancer Res,2004
2. Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance;Hochhaus;Leukemia,2004
3. Loss of p53 impedes the antileukemic response to Bcr-Abl inhibition;Wendel;Proc Natl Acad Sci U S A,2006
4. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development;Burchert;Leukemia,2005
5. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2;Dai;J Biol Chem,2004
Cited by 62 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The potential of circHIPK3 as a biomarker in chronic myeloid leukemia;Frontiers in Oncology;2024-03-05
2. ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma;Oncogene;2022-03-18
3. Changes of Dentition State in Leukemic Patients during Chemotherapy;International Journal of Environmental Research and Public Health;2021-08-02
4. Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells;Archives of Medical Science;2021-01-05
5. Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients;Scientific Reports;2020-11-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3